| Document |
Document Title |
|
WO/2017/190715A1 |
The invention relates to a preparation method of an amorphous form of sofosbuvir of formula I, (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2
H)-yl)-4- fluoro-3-hydroxy-4-memyltetrahydrofuran-2-yl)methoxy)-(ph...
|
|
WO/2017/192902A1 |
Disclosed herein are novel methods and compositions for rapidly extracting and amplifying nucleic acids from a sample where the sample is combined with an extraction reagent comprising a reducing agent to form a mixture and incubating sa...
|
|
WO/2017/185900A1 |
Provided are a series of crocins compounds and related pharmacological application thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasmi...
|
|
WO/2017/185549A1 |
Provided is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP, and ribose react under the catalytic effects of nicotinamide phosphoribosyltransferase, phosphoribose pyrophosphokinase, and ribokinase so a...
|
|
WO/2017/182965A1 |
The invention relates to a method for obtaining an N-acetylglucosamine containing neutral oligosaccharide from a fermentation broth, wherein said oligosaccharide is produced by culturing a genetically modified microorganism capable of pr...
|
|
WO/2017/180592A1 |
The present disclosure provides, in some aspects, methods and compositions for producing nucleic acid nanostructures having little to no kinetic barriers to self-assembly.
|
|
WO/2017/177896A1 |
Disclosed in the present invention are a compound represented by formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition o...
|
|
WO/2017/178664A1 |
The present invention relates to the preparation of a synthetic tetrasaccharide, hexasaccharide and octasaccharide representing part of the repeating unit of the Streptococcus pneumoniae type 3 capsular polysaccharide as well as conjugat...
|
|
WO/2017/176010A1 |
The present invention relates to a novel method for purifying 3,6-anhydro-L-galactose by using microorganisms and provides an effect of improving the production yield of 3,6-anhydro-L-galactose by using microorganisms during purification...
|
|
WO/2017/167168A1 |
Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids having more than three galloyl moieties, methods of preparing such, and uses the...
|
|
WO/2017/161986A1 |
A natural extract high-intensity sweetener steviol glycoside, specifically related to a novel steviol C-glycoside crystal, a preparation method for same, and applications thereof. The novel crystal has the advantages of high crystallinit...
|
|
WO/2017/161987A1 |
The present invention relates to the naturally extracted high intensity sweetener stevioside, and specifically relates to a novel crystal form of steviolbioside, and a manufacturing method and application therefor. The novel crystal form...
|
|
WO/2017/162169A1 |
The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer there...
|
|
WO/2017/161985A1 |
The present invention relates to a naturally-extracted high-sweetener stevioside, and in particular to a new crystal form of a rebaudioside B, and a preparation process therefor and a use thereof. The new crystal form is fully characteri...
|
|
WO/2017/160672A1 |
Modified Tryptamine, Tryptamine-2'-deoxy-uridine (TrpdU) and TrpdU-phosphoramidites for oligonucleotide synthesis are provided, as well as improved methods of their synthesis and oligonucleotides comprising at least one modified TrpdU nu...
|
|
WO/2017/158624A1 |
The present disclosure provides novel crystalline sofosbuvir form- M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage ...
|
|
WO/2017/160846A1 |
A method for making a highly soluble steviol glycoside composition is described. The resulting composition readily provides aqueous solutions with at least 0.3% concentration.
|
|
WO/2017/153452A1 |
The present invention relates to a method for preparing 2'-O-fucosyllactose and to the protected fucosyl donor of the formula (I) used in this method. The method comprises reacting the fucose derivative of the formula (I) below with the ...
|
|
WO/2017/152918A1 |
The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ...
|
|
WO/2017/150766A1 |
Disclosed herein is a method of producing D-psicose. The method of producing D-psicose includes subjecting D-fructose to D-psicose epimerization to produce a D-psicose-containing solution, subjecting the D-psicose-containing solution to ...
|
|
WO/2017/151742A1 |
The present invention provides a method of enriching a lipopeptide in a microbial cell culture, the method comprising mixing an amphiphilic sulfonate and/or an amphiphilic sulfate with the cell culture to induce the formation of aggregat...
|
|
WO/2017/144318A1 |
The invention relates to derivatives of rhamnolipids of formula (I), formulations containing same, and the use thereof, in particular for scent retention on hair.
|
|
WO/2017/144829A1 |
The field of this invention is that of recycling sugars from the by-products of the paper and cellulose industries and lignocellulosic biorefineries. The aim of the invention is to facilitate extraction and purification of sugars contain...
|
|
WO/2017/145151A1 |
Disclosed herein is a process for preparing nicotinamide riboside (NR) from an NR precursor and a phosphate-binding agent in a solvent. The reaction-derived mixture comprising NR may be further used without further processing in a variet...
|
|
WO/2017/144317A1 |
The invention relates to ester derivatives of rhamnolipids of formula (I) as nonionic surfactants, formulations containing same, and the use thereof.
|
|
WO/2017/143956A1 |
The present invention relates to a naturally-extracted high potency sweetener rebaudioside, and particularly relates to a novel crystal form of a sodium salt of rebaudioside B and a preparation method thereof. The novel crystal form is c...
|
|
WO/2017/144423A1 |
The present invention relates to a process for the synthesis of Sofosbuvir of formula (I) comprising the selective mono-deacetylation reaction of a compound of formula (V) to obtain a compound of formula (IV).
|
|
WO/2017/133465A1 |
The present invention relates to a baicalin magnesium and further relates to a preparation method and extraction method of the baicalin magnesium. The preparation method comprises the steps of preparing a suspension of a baicalin, prepar...
|
|
WO/2017/134176A1 |
The present invention relates to a process for producing 2'-O-fucosyllactose, to the intermediates obtainable by this process and to the use of these intermediates. Production comprises the reaction of a protected fucose of general formu...
|
|
WO/2017/134606A1 |
The present invention relates to a crystalline Form B of {(1 R,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxybenzylphenyl]- 2,3,4-trihydroxy- 6,8-dioxabicyclo [3.2. 1]oct-1-yl}methyl acetate of Formula (II) and a process for its preparation. The p...
|
|
WO/2017/124222A1 |
Disclosed are a method and an intermediate for preparing a tulathromycin. The method comprises the following step: in an organic solvent, subjecting a compound represented by formula (II) and an n-propylamine to a ring-opening addition s...
|
|
WO/2017/124970A1 |
Provided are a dicaffeoyl-spermidine derivative glycoside, a preparation method therefor and a use. Biological activity tests show that the dicaffeoyl-spermidine derivative glycoside has antioxidant activity and antiviral activity, the a...
|
|
WO/2017/124969A1 |
Provided are a dicaffeoyl-spermidine cyclic derivative and a use. Biological activity tests show that the dicaffeoyl-spermidine cyclic derivative has anti-senile dementia activity and antioxidant activity, the activity of the derivative ...
|
|
WO/2017/120729A1 |
The present invention discloses a method and an intermediate for the preparation of an epirubicin hydrochloride. The method comprises the following step: in an organic solvent and under an action of an alkali, subjecting compound 4 and a...
|
|
WO/2017/118355A1 |
Provided in the present application are a nucleotide derivative of a deuterated HCV (Hepatitis C Virus) NS5b inhibitor, or a pharmaceutically acceptable salt, stereoisomer, tauromer inhibitor thereof, and a use thereof in the preparation...
|
|
WO/2017/118690A1 |
The present invention relates to an efficient route of synthesis of solithromycin and to a method of its purification which obviates the necessity of chromatographic purifications and improves the quality of the product by efficiently re...
|
|
WO/2017/109023A1 |
The present invention relates to a method of preparing an oligosaccharide composition, said method comprising the steps of: (a)providing a pectin; and (b)performing, in any order, conversion of carboxylic acid groups to the corresponding...
|
|
WO/2017/101953A1 |
The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.
|
|
WO/2017/101785A1 |
Disclosed in the present invention are a prodrug comprising a nucleoside analog structure as shown in formula I, a tautomer thereof, a stereisomer thereof, a stereisomer mixture thereof or a pharmaceutically acceptable solvate thereof. A...
|
|
WO/2017/101890A1 |
The present invention relates to a spiroketal derivative having formula (I), a preparation method therefor and an application. R1, R2, R3, R4, X and the A ring are defined in the description. The derivative is an intestine or kidney gluc...
|
|
WO/2017/100618A1 |
This disclosure relates to methods of producing glycans from samples containing glycoconjugates using a salt of a hypohalous acid. Methods for producing N-glycans, O-glycans and lipid linked-glycans are provided. Compositions with novel ...
|
|
WO/2017/098252A1 |
The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-p...
|
|
WO/2017/098175A1 |
The present invention relates to a novel process for preparing compositions comprising alkyl(alkyl-glucoside)uronates, from biobased or biocompatible/biodegradable raw materials, and also salts and acids thereof.
|
|
WO/2017/098058A1 |
Methods of extracting lactose from whey are disclosed herein. Such methods can include removing water from the whey, thereby causing precipitation of lactose from the whey. The resulting heterogeneous mixture may be passed through one or...
|
|
WO/2017/093973A1 |
The present invention provides pure sofosbuvir and a process for the preparation of pure sofosbuvir and its intermediates.
|
|
WO/2017/088839A1 |
This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containi...
|
|
WO/2017/084958A1 |
The invention relates to a process for obtaining an aqueous extract enriched with small RNAs having a maximum length of 150 nucleotides from a plant material. The invention is characterized in that it comprises the following steps accord...
|
|
WO/2017/087245A1 |
The invention relates to a topical composition comprising an extract of Tiger lily (Lilium tigrinum) enriched in low molecular weight RNA. The invention also relates to a method of cosmetic care including the topical application a compos...
|
|
WO/2017/085144A1 |
The invention relates to new compounds of formulae: Wherein: R 1 and R 2 can be independently H; a C 1 to C 6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R 1, R 2 together with the carbon C...
|
|
WO/2017/080313A1 |
Provided a compound of formula (I): or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the compound is tetrahydropalmatine deriv...
|
